BFLY vs TGTX
Butterfly Network, Inc. vs TG Therapeutics, Inc. — AI-powered side-by-side comparison
BFLY
Butterfly Network, Inc.
67
Buy
VS
TGTX
TG Therapeutics, Inc.
60
Watch
| Metric | BFLY | TGTX |
|---|
| AI Score |
67
|
60
|
| Price |
$9.36
|
$49.86
|
| P/E Ratio |
-32.38×
|
16.39×
|
| ROE |
-39.3%
|
69.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
51.1%
|
82.4%
|
| Debt / Equity |
0.10×
|
1.25×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
66.4
|
42.0
|
| Beta |
2.084
|
1.666
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for BFLY versus TGTX.
BFLY leads by 7 points.
BFLY scores 67/100 (Buy) versus TGTX at 60/100 (Watch).
BFLY Committee View
67% agreement
6 analysts
The primary driver is revenue growing 28.1% yoy -- genuine top-line momentum. The main limiting factor is roe of only -38.4% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 28.1% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -38.4% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 52.6% signals elevated volatility — Risk
TGTX Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 76.1% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 22.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 72.3% shows genuine earnings power backing the valuation — Value
- Revenue growing 76.1% YoY -- genuine top-line momentum — Growth
- EPS growing 633.7% YoY — Growth
Bear Case
- Price-to-book of 21.1x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 22.5% signals elevated volatility — Risk